UY38352A - Inhibidores de integrina alfavbeta6 - Google Patents

Inhibidores de integrina alfavbeta6

Info

Publication number
UY38352A
UY38352A UY0001038352A UY38352A UY38352A UY 38352 A UY38352 A UY 38352A UY 0001038352 A UY0001038352 A UY 0001038352A UY 38352 A UY38352 A UY 38352A UY 38352 A UY38352 A UY 38352A
Authority
UY
Uruguay
Prior art keywords
alfavbeta6
integrin inhibitors
integrin
inhibitors
prevention
Prior art date
Application number
UY0001038352A
Other languages
English (en)
Inventor
S Lippa Blaise
A Harrison Bryce
E Dowling James
G Bursavich Matthew
M Troast Dawn
N Rogers Bruce
Cheng Zhong
Lin Fu-Yang
Brian Sosa
I Gerasyuto Aleksey
Andrea Bortolato
A Svensson Mats
Eugene Hickey
D Konze Kyle
Tyler Day
Byungchan Kim
Original Assignee
Morphic Therapeutic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphic Therapeutic Inc filed Critical Morphic Therapeutic Inc
Publication of UY38352A publication Critical patent/UY38352A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen inhibidores de integrina alfavbeta6 de moléculas pequeñas, y métodos para usarlos en el tratamiento o prevención de diversas enfermedades y condiciones.
UY0001038352A 2018-08-29 2019-08-29 Inhibidores de integrina alfavbeta6 UY38352A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862724397P 2018-08-29 2018-08-29

Publications (1)

Publication Number Publication Date
UY38352A true UY38352A (es) 2020-03-31

Family

ID=70284760

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038352A UY38352A (es) 2018-08-29 2019-08-29 Inhibidores de integrina alfavbeta6

Country Status (6)

Country Link
US (1) US20230242524A1 (es)
EP (1) EP3844162A4 (es)
AR (1) AR116036A1 (es)
TW (2) TWI835840B (es)
UY (1) UY38352A (es)
WO (1) WO2020081154A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3054792A1 (en) 2017-02-28 2018-09-07 Morphic Therapeutic, Inc. Inhibitors of .alpha.v.beta.6 integrin
MA47697A (fr) 2017-02-28 2020-01-08 Morphic Therapeutic Inc Inhibiteurs de l'(alpha-v)(bêta-6) intégrine
JP7540998B2 (ja) 2018-08-29 2024-08-27 モーフィック セラピューティック，インコーポレイテッド αｖβ６インテグリンの阻害
WO2024173570A1 (en) * 2023-02-14 2024-08-22 Morphic Therapeutic, Inc. INHIBITING αvβ8 INTEGRIN

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
TR200002557T2 (tr) * 1997-12-17 2000-12-21 Merck & Co., Inc. İntegrin reseptörü antagonistleri
US6017926A (en) * 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
JP2003502373A (ja) * 1999-06-23 2003-01-21 メルク エンド カムパニー インコーポレーテッド インテグリン受容体アンタゴニスト
GB201417094D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417011D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
CN114805342A (zh) * 2015-02-19 2022-07-29 赛弗卢尔生命科学公司 氟化四氢萘啶基壬酸衍生物及其用途
GB201604681D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
EP3558303A4 (en) * 2016-12-23 2020-07-29 Pliant Therapeutics, Inc. AMINO ACID COMPOUNDS AND METHOD FOR USE
MA47697A (fr) 2017-02-28 2020-01-08 Morphic Therapeutic Inc Inhibiteurs de l'(alpha-v)(bêta-6) intégrine

Also Published As

Publication number Publication date
AR116036A1 (es) 2021-03-25
EP3844162A1 (en) 2021-07-07
TW202423925A (zh) 2024-06-16
WO2020081154A1 (en) 2020-04-23
US20230242524A1 (en) 2023-08-03
TW202019928A (zh) 2020-06-01
TWI835840B (zh) 2024-03-21
EP3844162A4 (en) 2022-05-25

Similar Documents

Publication Publication Date Title
UY38353A (es) Inhibición de integrina alfavbeta6
CL2021000084A1 (es) Inhibidores de pd-1/pd-l1
CL2018002359A1 (es) Métodos para usar agonistas de fxr
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CO2020009861A2 (es) Inhibidores pd-1/pd-l1
CL2019003144A1 (es) Formulaciones de anticuerpos anti-lag3 y co-formulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
CO2019004003A2 (es) Composiciones y anticuerpos anti-lag-3
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
BR112018008326A2 (pt) composições e métodos para o tratamento de câncer
DOP2015000304A (es) Inhibidores cristalinos de bromodominios
UY38352A (es) Inhibidores de integrina alfavbeta6
CL2018002698A1 (es) Tratamiento de enfermedades inflamatorias con inhibidores de actividad c5a
CL2018001226A1 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
ECSP22038978A (es) INHIBICIÓN DE INTEGRINA ALFA4ß7 HUMANA
BR112016022855A2 (pt) composições e métodos para modular a expressão de pkk
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
CL2020003249A1 (es) Antagonista gremlin-1 para la prevención y tratamiento del cáncer
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
CO2018013020A2 (es) Combinaciones farmacéuticas para el tratamiento del cáncer
BR112018070497A2 (pt) métodos e formulações farmacêuticas para tratamento de condições oculares
CL2022000531A1 (es) Composiciones y métodos para el tratamiento de infecciones virales.
BR112018009745A8 (pt) compostos heterocíclicos para o tratamento de doença
BR112018005331A2 (pt) inibidores de pcna